-Bloomberg
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO’s Price Target
On Monday, REGENXBIO Inc (NASDAQ:RGNX) announced a program update from its ongoing clinical investigation of RGX-314 for wet AMD, a leading cause…
Related Posts
Full House Resorts’ Q4 Earnings Top Estimates
Full House Resorts Inc (NASDAQ:FLL) reported fourth-quarter FY21 sales growth of 13.1% year-on-year, to $43.3 million, beating the consensus of $43.28…
Blue Blood Final Four: How To Watch And A Betting Preview For UNC Vs. Duke, Villanova Vs. Kansas
The field of 68 teams that kicked off the 2022 NCAA Men’s Basketball Tournament is down to four teams that will compete for a chance to go to the championship game and be last team standing.
American Airlines Stock Takes Off, Options Traders See It Grounded Soon
American Airlines (NASDAQ: AAL) rebounded over 6% Tuesday after the stock gapped down on Monday amid concerns over the rapid spread of the COVID-19 Delta variant and how it may impact travel.